Citations 2
A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.
Polish, Ariel, Abbinanti, Susan, Vintilescu, Claudia Roxana, Rademaker, Alfred , Humphreys, Catherine, Cehic, Rasima, McFarland, Thomas, Tine, Brian Andrew Van, Okuno, Scott H. , Agulnik, Mark , Nye, Lauren Elizabeth , Humphreys, Catherine, Milhem, Mohammed , Skubitz, Keith M.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS10604-TPS10604
Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma
Attia, Steven , Okuno, Scott H. , Webber, Nicholas , Indelicato, Daniel J. , Jones, Robin L. , Sherman, Courtney E. , Kozak, Kevin R. , Cortese, Cherise , McFarland, Thomas, Trent, Jonathan C., Maki, Robert G. , Robinson, Steven I. , Sherman, Courtney, Cortese, Cherise M, Bagaria, Sanjay P. , Maki, Robert G , Jones, Robin L , Indelicato, Daniel J
Rare Tumors | June 15, 2015 | Volume: 7 | Issue: 2 | Pages: 86-88
We report a response to pazopanib in a 69-year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing.